Androgenetic Alopecia

Androgenetic alopecia is the medical term for inherited pattern hair loss. It occurs when genetically susceptible scalp follicles respond to androgen signalling by producing progressively shorter, finer hairs. Men often notice temple recession and crown loss, while women commonly see a widening central part and reduced upper-scalp density. The condition is progressive, but early treatment can preserve active follicles and improve coverage. Diagnosis is important because temporary shedding, traction and...

Androgenetic Alopecia

Androgenetic alopecia is the medical term for inherited pattern hair loss. It occurs when genetically susceptible scalp follicles respond to androgen signalling by producing progressively shorter, finer hairs. Men often notice temple recession and crown loss, while women commonly see a widening central part and reduced upper-scalp density. The condition is progressive, but early treatment can preserve active follicles and improve coverage. Diagnosis is important because temporary shedding, traction and inflammatory alopecia can overlap with the same visible thinning and require different management. Standardised photographs and part-width measurements are more useful than daily shed counts for tracking gradual change. Evidence-based treatments require consistent use and have limitations, risks and maintenance needs. Sudden loss, marked itching, pain, heavy scale or smooth scar-like areas should prompt assessment for a different or additional condition.

What Is Androgenetic Alopecia?

Each follicle cycles through growth, transition and rest. In androgenetic alopecia, the active growth phase shortens while the resting interval becomes relatively longer. Terminal hairs gradually become intermediate and vellus-like strands through a process called miniaturisation. A follicle can remain present yet produce a hair too fine to provide meaningful coverage.

Dihydrotestosterone, or DHT, is produced from testosterone by the enzyme 5-alpha reductase. Follicular sensitivity to DHT is more important than simply having a high blood testosterone level.

Signs of androgenetic alopecia

  • Slow recession at one or both temples
  • Progressive thinning around the crown
  • A wider central part or Christmas-tree distribution
  • Mixed thick and very fine strands in affected zones
  • Reduced ponytail circumference and styling volume
  • Gradual progression without heavy scalp inflammation

Sudden smooth patches, thick scale, pustules, pain, burning or loss of follicular openings are not typical and should be evaluated promptly.

Male and female presentations compared

FeatureCommon male presentationCommon female presentation
Starting areaTemples or crownCentral part or upper scalp
Frontal hairlineOften recedes into an M shapeUsually relatively preserved
Advanced patternFront and crown areas may connectDiffuse central thinning, rarely complete baldness
Hormone testingUsually unnecessary in a classic patternConsidered when androgen symptoms are present
Core therapyMinoxidil with or without DHT reductionMinoxidil with selected anti-androgen options

Genetics and risk

Inheritance is polygenic, meaning many genetic variants contribute. Family history from both maternal and paternal sides is relevant, but an affected relative does not determine the exact onset or severity. Age increases prevalence, yet androgenetic alopecia can begin soon after puberty.

Environmental stress does not create the genetic condition, although illness or severe stress can cause telogen effluvium that reveals previously subtle miniaturisation.

How dermatologists make the diagnosis

  1. History: onset, rate, shedding, family pattern, medicines and hormonal symptoms are reviewed.
  2. Distribution: density is compared across frontal, central, crown and donor regions.
  3. Dermoscopy: magnification reveals hair-diameter diversity and miniaturised strands.
  4. Pull test: this identifies simultaneous active shedding.
  5. Selective investigation: blood tests or biopsy clarify atypical cases.

Women with irregular periods, increased facial hair, infertility or severe acne may need assessment for androgen excess or polycystic ovary syndrome. Most women with female pattern loss do not have abnormal hormone levels.

Topical minoxidil

Minoxidil is approved in many settings for pattern hair loss. It prolongs anagen growth and enlarges some miniaturised follicles. Foam and solution products differ in strength and application schedule. Apply the recommended amount directly to dry scalp and remain consistent.

  • Temporary shedding may occur during early use.
  • Visible change commonly needs three to six months.
  • Maximum assessment may require twelve months.
  • Benefit gradually fades after discontinuation.
  • Wash hands and prevent transfer to the face.

Scalp irritation and unwanted facial hair can occur. Seek advice for dizziness, swelling, chest discomfort or palpitations. Pregnancy, breastfeeding and cardiovascular conditions require professional discussion.

Finasteride and dutasteride

Finasteride inhibits type II 5-alpha reductase and lowers scalp and circulating DHT. It can slow progression and improve density in many men. Dutasteride inhibits type I and type II forms and may be prescribed off-label in selected cases. Neither medicine creates immediate regrowth.

Potential sexual, reproductive, breast and mood-related adverse effects should be discussed. Pregnant people should not handle broken finasteride or dutasteride capsules or tablets because of fetal risk. Use in women requires specialist selection and reliable pregnancy prevention where relevant.

Spironolactone for selected women

Spironolactone blocks androgen effects and is used off-label for some women, particularly when acne, hirsutism or other androgen features coexist. It can affect blood pressure, potassium and menstrual cycles and is unsuitable during pregnancy. Medication review and monitoring are necessary.

Low-dose oral minoxidil

Oral minoxidil is increasingly used off-label when topical application is impractical or irritating. Possible effects include excess facial or body hair, ankle swelling, headache, rapid pulse and blood-pressure changes. Dosing and monitoring must be clinician directed, especially with cardiovascular or kidney conditions.

Supportive hair and scalp care

  • Shampoo often enough to control oil and dandruff.
  • Condition lengths to reduce tangles and breakage.
  • Avoid tight styles and heavy extensions.
  • Limit bleach overlap and repeated high heat.
  • Protect visible scalp from ultraviolet exposure.

Good grooming preserves shaft quality but does not alter androgen sensitivity. Washing, ordinary hats and cutting do not cause miniaturisation. Oils may reduce friction, yet they cannot reliably lower follicular DHT.

Nutrition and concurrent shedding

Iron deficiency, thyroid disease, inadequate protein and rapid weight loss can add diffuse shedding to pattern loss. Targeted testing is helpful when the history includes heavy periods, restricted diet, digestive problems, fatigue or sudden increased fall. Correcting deficiency may improve the temporary component but does not cure androgenetic alopecia.

Biotin deficiency is rare, and high doses distort laboratory tests. Excess vitamin A and selenium can worsen loss. Supplements should address demonstrated need.

Platelet-rich plasma and low-level light

Platelet-rich plasma injections may improve density for some patients, but preparation, injection and maintenance protocols vary. Low-level laser or light devices can offer modest benefit when used repeatedly. Evidence is less standardised than for minoxidil and finasteride, so cost, effort and realistic effect should be discussed.

Hair transplantation

Transplantation moves relatively androgen-resistant follicles from a donor zone to thinning regions. Follicular unit extraction removes individual units, while strip surgery removes a narrow donor strip. Neither method creates new follicles or prevents native hair from continuing to miniaturise.

  • Confirm adequate donor density and scalp health.
  • Plan a hairline that remains natural with age.
  • Reserve donor grafts for future progression.
  • Understand scarring and poor-growth risks.
  • Continue medical treatment when recommended.

Camouflage and styling

Hair fibres, tinted scalp powder and strategic cutting reduce scalp contrast temporarily. Scalp micropigmentation imitates tiny follicles and works best with an experienced hygienic practitioner. Avoid heavy attachment systems that create traction, particularly on miniaturised edges.

Common androgenetic alopecia myths

  • Only maternal relatives do not determine inheritance.
  • A high testosterone result is not required for diagnosis.
  • Shaving does not increase follicle number or diameter.
  • Onion juice and oils do not replace DHT treatment.
  • Successful medication generally needs ongoing use.

When to seek dermatologist care

Early evaluation is useful when the part, crown, temples or hairline progressively change. Prompt assessment is needed for pain, burning, heavy scale, pustules, eyebrow loss or smooth areas because these suggest another disorder. Dermoscopy can confirm miniaturisation and establish a baseline before advanced loss.

Realistic treatment goals

Stabilising progression is a meaningful success. Thickening usually becomes visible after six to twelve months and varies by location and disease stage. Effective medication must continue to preserve benefit. Monthly photographs with consistent light, part and camera distance offer the clearest comparison. An evidence-based long-term plan protects more hair than repeatedly switching to products promising permanent, immediate reversal.

Find your starting point

Explore related topics

Start with skin, hair or body. Find guidance that speaks to your everyday concerns.

Androgenetic Alopecia: FAQs

Answers to common questions about Androgenetic Alopecia.

It is inherited pattern hair loss in which androgen-sensitive follicles gradually produce finer, shorter strands.
Yes. Multiple genes from both sides of the family influence risk, onset and progression.
Yes. Women commonly develop central part widening and upper-scalp thinning, often without abnormal blood androgen levels.
There is no permanent cure, but ongoing treatment can slow progression and thicken active miniaturised follicles.
Yes. Consistent topical minoxidil can prolong growth and improve density, with results requiring several months.
Finasteride lowers DHT production, reducing the hormonal signal that miniaturises susceptible follicles in suitable patients.
It can be appropriate under medical supervision but may affect blood pressure, heart rate, fluid retention and body-hair growth.
No. Supplements correct genuine deficiency but do not change inherited follicular androgen sensitivity.
No. It redistributes donor follicles; untreated native hair may continue miniaturising and often needs maintenance.
Seek early care for progressive patterned thinning and prompt assessment when pain, inflammation, patches or scarring signs occur.